Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment tags : Europe save search
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - biospace.com/
OCS | News 0 d | $11.98 0.25% 0.25% 310K
|
n/a
|
| O: 0.36%
H: 0.18%
C: -2.76%
ocs-01 positive treatment for meeting trial results
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
Published: 2024-04-08 (Crawled : 09:00) - biospace.com/
CALT | $18.0825 -1.71% 1.9K
|
Health Technology
|
| O: -1.06%
H: 3.5%
C: 0.51%
patent cancer treatment for application
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
CANF | $1.97 -0.51% 0.0% 3.8K
|
Health Technology
|
| O: -0.45%
H: 2.27%
C: 2.27%
europe liver conference distribution pancreatic treatment namodenoson
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
Published: 2023-12-08 (Crawled : 21:00) - biospace.com/
VRTX | $404.93 1.25% 1.43% 1.1M
|
Health Technology
|
| O: 0.01%
H: 0.1%
C: -1.09%
CRSP | News M | $56.46 1.44% 1.42% 1.2M
|
Health Technology
|
| O: 1.22%
H: 8.3%
C: -9.19%
fda crispr disease approval cell treatment therapeutics
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
Published: 2023-12-06 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.73% 9.3K
|
Health Technology
|
| O: 0.0%
H: 4.17%
C: 4.17%
mn-166 europe patent treatment grant
Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting
Published: 2023-12-01 (Crawled : 15:00) - biospace.com/
JAZZ | $109.685 0.79% 0.78% 380K
|
Health Technology
|
| O: -0.25%
H: 1.25%
C: 0.99%
pharmaceuticals meeting
AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations
Published: 2023-11-06 (Crawled : 18:00) - biospace.com/
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
avb-101 fda treatment dementia clearance designation
Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav®
Published: 2023-10-23 (Crawled : 12:00) - biospace.com/
JAZZ | $109.685 0.79% 0.78% 380K
|
Health Technology
|
| O: -1.39%
H: 0.09%
C: -2.36%
xywav treatment pharmaceuticals
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-10-04 (Crawled : 08:00) - biospace.com/
TEVA | $13.01 1.01% 0.0% 8.9M
|
Health Technology
|
| O: 1.46%
H: 0.21%
C: -5.65%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
disease treatment collaboration teva sanofi
New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes
Published: 2023-09-29 (Crawled : 23:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: -0.05%
tepezza disease treatment thyroid eye
Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib
Published: 2023-09-27 (Crawled : 19:00) - biospace.com/
CALT | $18.0825 -1.71% 1.9K
|
Health Technology
|
| O: 2.26%
H: 1.71%
C: -0.54%
fda drug granted treatment designation therapeutics
Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress
Published: 2023-09-05 (Crawled : 16:00) - biospace.com/
STOK | $11.24 -0.09% -0.09% 600K
|
Health Technology
|
| O: -0.72%
H: 3.64%
C: -0.55%
stk-001 congress international treatment ongoing therapeutics
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
Published: 2023-08-16 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.73% 9.3K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.63%
mn-166 europe patent macular treatment grant
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe
Published: 2023-08-15 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.73% 9.3K
|
Health Technology
|
| O: 6.93%
H: 2.83%
C: 0.0%
mn-001 europe patent sclerosis treatment
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe
Published: 2023-08-14 (Crawled : 23:00) - globenewswire.com
MNOV | $1.34 -3.73% 9.3K
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: -3.75%
mn-001 europe patent treatment grant nash
TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED)
Published: 2023-06-26 (Crawled : 18:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.43%
H: 0.48%
C: 0.38%
tepezza disease active approved treatment thyroid brazil eye
Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia
Published: 2023-05-25 (Crawled : 20:00) - biospace.com/
AKBA | $1.365 0.37% 0.37% 2.1M
|
Health Technology
|
| O: -2.8%
H: 0.72%
C: -12.95%
vafseo europe australia anemia license treatment commercialization therapeutics agreement
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
Published: 2023-05-02 (Crawled : 16:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.04%
H: 0.04%
C: -0.21%
lupus treatment trial therapeutics phase 2
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
Published: 2023-04-25 (Crawled : 13:20) - biospace.com/
ACHL | $0.781 -1.14% -1.15% 110K
|
Manufacturing
|
| O: 5.88%
H: 0.0%
C: -6.67%
patent treatment tumor immunotherapy grant therapeutics
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
Published: 2023-03-22 (Crawled : 08:00) - biospace.com/
RLFTF | $1.45 11.45% 1.3K
|
n/a
|
| O: 5.0%
H: 0.95%
C: -4.76%
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: -2.93%
H: 2.79%
C: -2.32%
urea treatment collaboration therapeutics results
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.